Onward Medical N.V. (ONWD.BR)
EUR 4.78
(-1.65%)
EUR 4.78
(-1.65%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 20.64 Million EUR | 19.05% |
| 2022 | 17.34 Million EUR | -29.18% |
| 2021 | 24.48 Million EUR | 85.44% |
| 2020 | 13.2 Million EUR | 32.92% |
| 2019 | 9.93 Million EUR | 34.9% |
| 2018 | 7.36 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 6.13 Million EUR | 28.88% |
| 2024 Q2 | 6.13 Million EUR | 0.0% |
| 2023 Q1 | 5.55 Million EUR | -68.62% |
| 2023 FY | 35.26 Million EUR | 103.39% |
| 2023 Q4 | 4.76 Million EUR | -9.46% |
| 2023 Q3 | 5.26 Million EUR | -72.86% |
| 2023 Q2 | 19.37 Million EUR | 248.54% |
| 2022 Q1 | 4.58 Million EUR | -25.45% |
| 2022 Q3 | 5.19 Million EUR | -66.99% |
| 2022 Q4 | 17.71 Million EUR | 241.3% |
| 2022 Q2 | 15.72 Million EUR | 243.17% |
| 2022 FY | 17.34 Million EUR | -29.18% |
| 2021 Q1 | 2.88 Million EUR | 12.29% |
| 2021 FY | 24.48 Million EUR | 85.44% |
| 2021 Q4 | 6.14 Million EUR | 0.0% |
| 2021 Q3 | 6.14 Million EUR | 112.87% |
| 2021 Q2 | 2.88 Million EUR | 0.0% |
| 2020 Q2 | 1.54 Million EUR | 0.0% |
| 2020 Q3 | 2.57 Million EUR | 66.44% |
| 2020 Q1 | 1.54 Million EUR | 0.0% |
| 2020 FY | 13.2 Million EUR | 32.92% |
| 2020 Q4 | 2.57 Million EUR | 0.0% |
| 2019 FY | 9.93 Million EUR | 34.9% |
| 2018 FY | 7.36 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | -394.254% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 83.792% |
| Adocia SA | 15.62 Million EUR | -32.094% |
| Aelis Farma SA | 18.81 Million EUR | -9.703% |
| Biophytis S.A. | 14.33 Million EUR | -44.038% |
| Advicenne S.A. | 8.21 Million EUR | -151.309% |
| genOway Société anonyme | 16.73 Million EUR | -23.34% |
| IntegraGen SA | 5.35 Million EUR | -285.707% |
| Medesis Pharma S.A. | 1.56 Million EUR | -1219.53% |
| Neovacs S.A. | 10.34 Million EUR | -99.593% |
| NFL Biosciences SA | 4.37 Million EUR | -371.956% |
| Plant Advanced Technologies SA | 2.76 Million EUR | -646.695% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -1101.712% |
| Sensorion SA | 27.05 Million EUR | 23.689% |
| Theranexus Société Anonyme | 3 Million EUR | -587.025% |
| TME Pharma N.V. | 5.49 Million EUR | -275.568% |
| Valbiotis SA | 9.86 Million EUR | -109.19% |
| TheraVet SA | 1.64 Million EUR | -1155.54% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | -1.599% |
| argenx SE | 1.34 Billion EUR | 98.462% |
| BioSenic S.A. | 7.58 Million EUR | -172.254% |
| Celyad Oncology SA | 8.49 Million EUR | -143.168% |
| DBV Technologies S.A. | 89.4 Million EUR | 76.909% |
| Galapagos NV | 327.98 Million EUR | 93.706% |
| Genfit S.A. | 54.8 Million EUR | 62.329% |
| GeNeuro SA | 14.35 Million EUR | -43.794% |
| Hyloris Pharmaceuticals SA | 17.98 Million EUR | -14.777% |
| Innate Pharma S.A. | 64.57 Million EUR | 68.027% |
| Inventiva S.A. | 120.18 Million EUR | 82.822% |
| MaaT Pharma SA | 21.59 Million EUR | 4.412% |
| MedinCell S.A. | 32.92 Million EUR | 37.291% |
| Nanobiotix S.A. | 58.92 Million EUR | 64.965% |
| Oryzon Genomics S.A. | 18.49 Million EUR | -11.612% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | 12.48% |
| Oxurion NV | 12.21 Million EUR | -69.027% |
| Pharming Group N.V. | 204.24 Million EUR | 89.892% |
| Poxel S.A. | 28.76 Million EUR | 28.229% |
| GenSight Biologics S.A. | 32.66 Million EUR | 36.788% |
| Transgene SA | 31.23 Million EUR | 33.896% |
| Financière de Tubize SA | 114.38 Thousand EUR | -17948.064% |
| UCB SA | 2.94 Billion EUR | 99.298% |
| Valneva SE | 134.92 Million EUR | 84.699% |
| Vivoryon Therapeutics N.V. | 24.69 Million EUR | 16.39% |